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Summary 
Background: Propolis and N-acetylcysteine have positive
impact on respiratory tract health. Also, it has been sug-
gested that they have beneficial effects on serum lipid and
oxidative stress status, but the available data are limited
and mostly gained from animal models. In this study we
evaluated the effects of propolis and N-acetylcysteine sup-
plementation (PropoMucil®) on lipid status, lipoprotein
subclasses distribution and paraoxonase 1 activity in sub-
jects with acute respiratory infection.
Methods: Twenty subjects with acute respiratory infection
were included. PropoMucil® granules for oral solution (80
mg of dry propolis extract and 200 mg of N-acetylcysteine)
were administered tree times per day for ten days. Serum
lipid profile, paraoxonase 1 activity and low-density and
high-density lipoprotein size and subclasses distribution
were assessed at baseline and after supplementation.
Results: Following ten days of supplementation lipid status
remained unchanged, but a significant increase of low-
density lipoprotein particle size and proportion of high-den-
sity lipoprotein 3a particles were found (P<0.05).
Moreover, supplementation with PropoMucil® significantly
improved high-density lipoprotein particles distribution,
Kratak sadr`aj
Uvod: Propolis i N-acetilcistein pozitivno uti~u na zdravlje
disajnih puteva. Tako|e, sugeri{e se da oni imaju
blagotvorno dejstvo na lipidni i oksidativno-stresni status,
ali podaci su ograni~eni i dobijeni uglavnom na `ivotinjskim
modelima. U ovom istra ̀ ivanju, procenili smo kombinovani
efekat propolisa i N-acetilcisteina (PropoMucil®) na status
lipida, raspodelu subklasa lipoproteina i aktivnost para -
oksonaze 1 kod pacijenata sa akutnom respiratornom
infekcijom (ARI). 
Metode: Uklju~eno je 20 ispitanika sa akutnom respira-
tornom infekcijom. Oralni rastvor pra{ka Propo Mucil® (80
mg suvog ekstrakta propolisa i 200 mg N-acetilcisteina) je
aplikovan 3 puta dnevno tokom 10 dana. Serumski lipidni
profil, aktivnost praoksonaze 1 i veli~ina i raspodela sub-
frakcija lipoproteina niske gustine i lipoproteina visoke gus-
tine su odre |eni pre i nakon suplementacije. 
Rezultati: Nakon deset dana suplementacije, lipidni status
je ostao nepromenjen, ali je utvr|eno zna~ajno pove}anje
veli~ine lipoproteina niske gustine i relativnog udela lipo -
proteina visoke gustine 3a  (P <0,05). Pored toga, suple-
mentacija PropoMucil®-om zna~ajno je pobolj{ala distri -
buciju lipoproteinskih ~estica visoke gustine, posebno kod
List of abbreviations: ARI, acute respiratory infection; CAPE,
caffeic acid phenetyl ester; CRP, C-reactive protein; EDTA,
ethylen diamino tetraacetic acid; GSH, glutathione; HDL, high
density lipoprotein; IQR, interquartile range; LCAT, lecithin:
cholesterol acyltransferase; LDL, low density lipoprotein; MED,
multi extraction technology; NAC, N-acetylcysteine; PCB, poly-
chlorinated biphenyls; PON1, paraoxonase 1; sdLDL, small
dense LDL; SREBP2, sterol regulatory element binding protein-
2; TC, total cholesterol; TG, triglycerides
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Introduction
Acute respiratory infections (ARI) are the most
common infective diseases of respiratory tract and
most frequently have viral aetiology (1). The detri-
mental effects of tobacco smoke on respiratory tract
health and predisposition of smokers for development
of ARI are also well recognised (2). 
Acute infection and inflammation affect lipopro-
tein metabolism, structure and functionality (3). In
particular, serum lipid profile in acute phase response
is characterised by elevated triglycerides (TG) and
reduced high-density lipoprotein cholesterol (HDL-C)
levels, while the concentration of total (TC) and low-
density lipoprotein cholesterol (LDL-C) might be nor-
mal or slightly elevated. In line with previous, similar
observations are reported in ARI (4). As chronic, low-
grade inflammation leads to profound disorders of
lipoprotein metabolism and dyslipidemia (5) and ARI
and smoking may be associated with chronic pul-
monary disease or chronic inflammatory state, distur-
bances in lipoprotein metabolism are more expected
to occur. Lipid peroxidation of LDL particles is the
common link between oxidative stress and dyslipi-
demia and the initial step in atherogenesis (6).
Another important link is paraoxonase 1 (PON1), an
enzyme associated with HDL particles, which protects
LDL against lipid peroxidation (7). 
In recent years, a great attention has been
focused on the use of functional food and dietary
supplements with antioxidant and hypolipidemic
activity (8, 9). Propolis is a natural product and com-
plex mixture of various bioactive compounds, which is
traditionally used to prevent or assist recovery from
the infection (10). Although based on limited data,
propolis supplementation showed beneficial effects in
the management of chronic diseases, such as dia-
betes (11) and certain types of cancers (12). A recent
double-blind, placebo-controlled study showed signif-
icant improvement of oxidative stress and lipid status
following 90 days of propolis supplementation (13).
Yet, the effects of propolis on lipoprotein size and sub-
classes profile and PON1 activity are still unknown.
One of most effective application of N-acetylcysteine
(NAC) is the therapy of respiratory diseases, due to its
mucolytic properties (14). In addition, NAC stimu-
lates biosynthesis of glutathione (GSH) and has a
direct antioxidative role as free radical scavenger
(14). It seems that NAC supplementation might have
beneficial effects on serum lipid and PON1 status,
but the available data is limited and mainly obtained
from animal models and in vitro studies (15, 16). 
Both, propolis and NAC have positive impact on
respiratory tract health and the efficiency of their
specific combination, PropoMucil® (Abela Pharm,
Belgrade, Serbia), was recently reported in children
and adolescents with ARI (17). However, no previous
study investigated the effects of this supplement on
lipid status. In the current study we conducted a
short-term supplementation (as indicated for acute
disease process) of 20 subjects with ARI with
PropoMucil®. The supplementation period corre-
sponds to the data of the previous study, demonstrat-
ing a significant improvement of ARI symptoms with
the same combination of propolis and NAC in major-
ity of pediatric patients after 10 days (17). The aim of
this study was to assess the effects of propolis and
NAC (PropoMucil®) supplementation on lipid status,
lipoprotein size and subclasses distribution and PON1
activity in subjects with ARI. 
Materials and Methods
Study subjects and protocol
The study included 20 subjects, 7 men and 13
women, aged 62.5 ± 15.0 years, who were referred
to the Municipal Institute for Lung Disease and
Tuberculosis, Belgrade, Serbia and, after clinical and
laboratory examination, diagnosed with ARI (acute
bronchitis). Among them, 30% were smokers. For all
the subjects, microbiological analysis of sputum and
C-reactive protein (CRP) concentration testing were
performed. The results of sputum analysis were neg-
ative for bacteria and CRP concentrations indicated a
viral infection. 
PropoMucil® 200 powder for oral solution
(Abela Pharm, Belgrade, Serbia), containing 80 mg
of dry propolis extract and 200 mg of NAC, were
administered tree times per day for 10 days to each
subject. According to the manufacturer specification,
PropoMucil® contains purified dry propolis extract
particularly in those who smoke. There was a moderate
increase of paraoxonase 1 activity, but without statistical
significance.
Conclusions: The presented study demonstrated that short-
term supplementation with PropoMucil® has beneficial
effects on low-density and high-density lipoprotein sub-
classes distribution and paraoxonase 1 activity in subjects
with acute respiratory infection particularly in those who
smoke.
Keywords: acute respiratory infection, antioxidants,
lipoproteins, N-acetylcysteine, propolis, smoking
pacijenata koji pu{e. Do{lo je do umerenog porasta aktiv -
nosti paraoksonaze 1, ali bez statisti~ke zna~ajnosti. 
Zaklju~ak: Studija je pokazala da kratkotrajna suplemen -
tacija PropoMucil®-om ima korisne efekte na distribuciju
subklasa lipoproteina niske i visoke gustine i aktivnost para -
oksonaze 1 kod ispitanika sa akutnom respiratornom infek-
cijom, posebno kod onih koji pu{e.
Klju~ne re~i: akutna respiratorna infekcija, anti oksi -
danti, lipoproteini, N-acetilcistein, propolis, pu{enje
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(20%), standardized to 12% of total polyphenols, with
20% of NAC. Propolis extract was obtained by
dynamic multi extraction technology (MED) and does
not contain resins, but is enriched in integral polyphe-
nols (phenolic acids, flavonoids, aglycons and gluco-
sides) (18).
All study participants completed 10 days sup-
plementation period and reported no allergy or any
other adverse effects. None of the subjects included
in the study received any other medications for ARI,
lipid-lowering therapy or antioxidant supplementation
at baseline and during the follow-up. At baseline and
following the supplementation the data on the pres-
ence/absence of cough and expectoration, as well as
sputum characteristics (clear/purulent) were record-
ed. Blood samples were also collected at baseline and
after 10 days of supplementation. At each time point
the blood was drawn after a 12-hour fasting period
into one evacuated tube containing EDTA and one
serum sample tube. The study was planned according
to the ethical guidelines following the Helsinki
Declaration and approved by the Ethics Committee at
the Faculty of Pharmacy, University of Belgrade and
Municipal Institute for Lung Disease and Tuber -
culosis. Informed consent was obtained from all study
participants. 
Laboratory analyses
Serum lipid parameters (TC, LDL-C, HDL-C and
TG) were measured by routine laboratory methods
and the concentration of CRP was measured by
immunoturbidimetric assay (Biosystems S.A., Bar ce -
lona, Spain) using an ILab300+ analyser (Instru -
mentation Laboratory, Milan, Italy). Plasma LDL and
HDL subclasses were separated by gradient gel elec-
trophoresis method, as it has been published else-
where (19). This method provides simultaneous
determination of LDL and HDL particle sizes and rel-
ative proportions of seven LDL and five HDL subclass-
es. The proportion of small, dense LDL particles
(sdLDL) was estimated by summing up relative pro-
portions of LDL III and IV subclasses (19). The activity
of PON1 was measured as a rate of paraoxon hydrol-
ysis, using the method developed by Richer and
Furlong (20), as modified in our laboratory and pub-
lished elsewhere (7).
Statistical analysis 
Data are shown as mean ± standard deviation
for normally distributed variables and as median and
lower and upper limits of interquartile range (IQR) for
non-normally distributed variables. Categorical vari-
ables are presented as absolute and relative frequen-
cies and compared by Chi-square test. We tested the
normality of all continuous variables, using Shapiro-
Wilk test. Non-normally distributed data were further
log transformed, but they failed to achieve normality,
and therefore were analysed by non-parametric tests.
Comparisons of baseline and the data after 10 days
of supplementation were performed by the paramet-
ric paired t-test for normally distributed data or by the
paired Wilcoxon’s signed-rank test for non-normally
distributed variables. The unpaired Mann-Whitney
Exact test was used to compare relative changes in
laboratory data between smokers and non-smokers.
Correlation analysis was performed by Spearman’s
rank correlation method.
Results
After 10 days of supplementation with Propo -
Mucil® all subjects reported improvement of the
symptoms, reflected by reduced intensity of cough in
17 subjects (85%) and reduced expectoration in 14
patients (70%). The number of patients having cough
was significantly reduced (100% at baseline vs. 70%
after supplementation; P<0.01), as well as the num-
ber of patients with purulent sputum (30% at baseline
vs. 0% after supplementation; P<0.01). 
Table I shows serum lipid parameters and PON1
activity at baseline and after 10 days of supplementa-
tion with PropoMucil® in all ARI patients. All evaluat-
ed parameters of lipid status remained unchanged
after supplementation. Also, we found a moderate
increase in PON1 activity after supplementation
which was not statistically significant. Finally, there
was a modest decrease in CRP levels after supple-
mentation, but the difference did not reach statistical
significance. 
Next, we evaluated the effects of supplementa-
tion on LDL and HDL particles characteristics (Table
II). After 10 days of PropoMucil® supplementation a
significant increase of LDL particles size was found. In
addition, the proportion of small HDL 3a particles was
significantly higher following supplementation period. 
In further analysis, we evaluated possible associ-
ations between relative changes of biochemical
parameters and lipoprotein size and subclasses distri-
bution. Spearman’s correlation analysis showed that
relative changes in TG levels after supplementation
were significantly inversely associated with the
changes in HDL 2b subclasses proportion (r = -
0.499; P=0.025), but positively with changes in the
proportion of HDL 3a particles (r = 0.460;
P=0.041). The changes in CRP levels significantly
positively correlated with the changes in proportions
of small LDL III particles (r = 0.638; P=0.038).
The effects of 10 days of supplementation on
serum lipid profile (Figure 1A) were more prominent
in the smokers, as indicated by increase of HDL-C
(median relative change of +9% in smokers vs. -0.3%
in non-smokers) and reduction of TG (median relative
change of -4.6% in smokers vs. +21.8% in non-
smokers), although with no significance. In addition,
the smokers with ARI experienced beneficial effects
on CRP and PON1 levels (Figure 1B). The supple-
mentation showed opposite effects on HDL subclass-
es distributions in smokers and non-smokers. In par-
ticular, the proportions of small HDL 3b and HDL 3c
particles were significantly reduced after supplemen-
tation in smokers with ARI (Figure 1D). Similarly, the
changes in LDL subclasses distribution was more pro-
nounced in smokers with ARI, yet without significance
(Figure 1C). 
Discussion
The results of the presented study demonstrated
that PropoMucil® has some beneficial effects on LDL
and HDL subclasses distribution in subjects with ARI.
Following 10 days of supplementation general lipid
status remained unchanged, but more depth analysis
showed that HDL 3 particles distribution was signifi-
cantly improved, particularly in those who smoke. The
supplementation with PropoMucil® did not signifi-
cantly affect PON1 activity.
Propolis is a mixture of various bioactive com-
pounds that contribute synergistically to its overall
effects (10). Regarding serum lipid profile, data from
animal models showed that propolis reduced LDL-C,
while increased HDL-C levels in the rabbits fed a
cholesterol-enriched diet (21). Available data suggest
that NAC also possess certain hypolipidemic effects
(15), probably as a consequence of improved insulin
sensitivity following NAC administration (22).
Although serum lipid parameters did not signifi-
cantly change after 10 days of supplementation
(Table I), beneficial effects on serum lipoprotein pro-
file was shown (Table II and Figure 1). There was a
significant increase in LDL size after 10 days of sup-
plementation (Table II), while the effect on LDL sub-
classes distribution was more pronounced in the
smokers with ARI (Figure 1). It has been reported that
quercetin, one of the most common flavonoid in
propolis, may upregulate LDL receptors synthesis in
HepG2 cells via protein kinases cascade activation of
sterol regulatory element binding protein-2 (SREBP-
2) (23). Increased receptors expression could be one
of the reasons for faster sequestration of pro-athero-
genic sdLDL particles from the circulation thereby
increasing the proportion of larger LDL particles and
dominant LDL size.
Plasma HDL populations are constituted by sev-
eral subfractions that differ in size, density and com-
position, ranging from HDL 3c, as the smallest and
the most dense, to HDL 2b, which are the largest and
the least dense particles. More importantly, different
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Figure 1 Relative changes of laboratory parameters after 10 days of supplementation in ARI smokers and non-smokers. A, Serum
lipid parameters; B, CRP concentration and PON1 activity; C, LDL subclasses; D, HDL subclasses. Data are compared by the
Mann-Whitney Exact test and presented as medians: * P<0.05; ** P<0.01.
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HDL subclasses have distinct metabolic behaviour
and anti-atherogenic properties (24). Data of our and
other groups consistently showed decreased propor-
tion of large HDL 2 and/or the abundance of smaller
HDL 3 particles in different categories of patients with
increased cardiovascular risk (25). Namely, smaller
HDL 3 particles, although essentially considered as
atheroprotective, might undergo structural changes
in pro-inflammatory conditions, which further com-
promise their functionality, as it was documented in
respiratory disease, too (26, 27). In line with previous,
our data showed that supplementation with
PropoMucil® significantly improved HDL particles dis-
tribution, as reflected by significant reduction of
smaller HDL 3 subclasses proportion in those who
smoke (Figure 1). Our results might be explained by
flavonoid-mediated regulation of some pathways in
lipoprotein metabolism. It was demonstrated that
rutin, another abundant flavonoid in propolis, increas-
es the activity of lecithin: cholesterol acyltransferase
(LCAT), an enzyme which mediates maturation of
HDL particles in plasma (28) leading to subsequent
reduction of smaller HDL particles. Also, changes in
the proportion of small HDL 3 particles in our study
were related to the changes in TG levels following
supplementation. All of the above may account for
more pronounced effects of the supplementation on
HDL subclasses distribution in smokers with ARI.
PON1 is a major antioxidant component of HDL
particles with an ability to hydrolyze lipid peroxides,
thus protecting LDL particles from oxidation (7). ARI
(3) and tobacco smoking (29) can contribute to
diminished enzyme activity. However, the inhibition is
reversible and PON1 activity can be restored by
antioxidants, such as NAC, or by caffeic acid phenetyl
ester (CAPE), a component of propolis (29, 30). Our
results showed no significant difference in PON1
activity at baseline and following supplementation
with PropoMucil® (Table I). In the recent study by
Shen et al. (16), NAC administration in the group of
rats exposed to polychlorinated biphenyls (PCB)
caused a significant increase in serum PON1 activity,
whereas such effect was not found in the control
group, suggesting potential interaction of PCB and
NAC on PON1 activity. Also, although there is evi-
dence in both cell cultures and animal models that
quercetin upregulates PON1 gene expression (31),
quercetin supplementation in humans had no signifi-
cant effects on PON1 activity (32). The observed
trend of greater increase of PON1 activity in smokers
indicate that additional studies, with more subjects
included, are necessary to elucidate the potential
effects of complex mixture of NAC and propolis sup-
plementation on PON1 activity.
A potential limitation of our study could be a
lack of a control or placebo group and small number
of subjects included. Nevertheless, a current study is
one of the few investigations of joined propolis and
NAC effects on lipid metabolism in humans and all
laboratory analyses were performed blindly, which
accounts for its strength. A relatively short supple-
mentation period could be a reason for the lack of dif-
ference in serum lipid parameters before and after
supplementation. However, the observed subtle
changes in lipoprotein particles distribution indicate
that this supplementation period was sufficient to
Table I Effect of supplementation on serum lipid parame-
ters, PON1 activity and CRP concentration in all ARI patients.
Data were compared by parametric paired t test and present-
ed as mean ± standard deviation.
# Data were compared by paired Wilcoxon’s signed-rank test
and presented as median (lower and upper limit of interquartile
range).
Table II Effect of supplementation on LDL and HDL size and
subclasses in all ARI patients.
Data were compared by parametric paired t-test and present-
ed as mean ± standard deviation.
Baseline After 10 days P
TC, mmol/L 4.89 ± 0.51 4.96 ± 0.39 0.339
LDL-C,
mmol/L 3.16 ± 0.49 3.19 ± 0.44 0.598
HDL-C,







PON1, U/L# 247.0 (226.5–472.0)
256.0 
224.5–507.0) 0.763
CRP, mg/L# 2.10 (1.20–3.10)
2.0 
(1.05–2.85) 0.919                             
Baseline After 10 days P
LDL size, nm 27.43 ± 0.63 27.64 ± 0.63 <0.05
LDL I, % 24.8 ± 3.8 23.7 ± 2.7 0.255
LDL IIA, % 11.3 ±1.5 11.0 ± 1.2 0.546
LDL IIB, % 14.0 ± 1.1 13.9 ± 1.7 0.758
LDL IIIA, % 12.7 ± 1.1 12.9 ± 1.0 0.564
LDL IIIB, % 7.2 ± 1.3 7.1 ± 0.9 0.799
LDL IVA, % 12.2 ± 2.3 13.0 ± 2.1 0.214
LDL IVB, % 18.2 ± 3.1 18.3 ± 2.6 0.785
sdLDL, % 50.2 ± 5.2 51.3 ± 4.1 0.320
HDL size, nm 9.82 ± 1.05 10.06 ± 0.96 0.176
HDL 2b, % 39.9 ± 4.81 38.88 ± 6.86 0.232
HDL 2a, % 22.1 ± 3.1 22.3 ± 1.8 0.688
HDL 3a, % 16.3 ± 2.1 17.3 ± 0.7 <0.05
HDL 3b, % 11.2 ± 0.5 11.2 ± 0.6 0.965
HDL 3c, % 10.5 ± 0.6 10.3 ± 0.8 0.664                             
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ascertain the effectiveness of the supplement.
Additional studies, designed for dyslipidemic patients,
are encouraged to verify our preliminary observa-
tions. 
In conclusion, the current study provides the
first data on positive effects of PropoMucil® supple-
mentation on plasma lipoprotein size and subclasses
distribution and PON1 activity in subjects with ARI
with more evident effects of supplementation
obtained in the group of smokers.
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